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Abstract
Background: Neoadjuvant short-course radiotherapy is used to reduce local recurrences in stage III rectal cancer.
Radiotherapy is not harmless, and meticulous total mesorectal excision surgery alone has been reported to result in
low local recurrence rate in favorable stage III tumors. The aim was to evaluate the effect of short-course (5 × 5 Gy)
radiotherapy on the local recurrence risk in patients with pT3N1-2 rectal cancer.
Materials and methods: This was a retrospective study with 151 consecutive pT3N1-2M0 rectal cancer patients
operated on at Helsinki University Hospital, Helsinki, Finland, during January 2005 to June 2014. Short-course
radiotherapy was given to 94 patients, and 57 patients were operated on without neoadjuvant radiotherapy.
The main outcome measurement was the effect of radiotherapy on local recurrence. Also, the risk factors for local
recurrence were analyzed.
Results: Local recurrence occurred in a total 17 of 151 (11.3%) patients, 8 of 57 (14.0%) in surgery only group
compared with 9 of 94 (9.6%) in radiotherapy plus surgery group (p = 0.44). In univariate Cox regression analysis,
the risk factors for local recurrence were tumor location under 6 cm from the anal verge (p = 0.01), involved lateral
margin (p < 0.001), tumor perforation (p < 0.001), and mucinous histology (p = 0.006). In multivariate analysis, risk
factors were tumor location under 6 cm from anal verge (p = 0.03) and involved lateral margin (p = 0.002).
Conclusion: Neoadjuvant short-course radiotherapy did not affect the local recurrence risk of pT3N1-2M0 rectal
cancer. Further studies with larger patient number are needed to evaluate the role of short-course radiotherapy in
different T3 subgroups (3a–c) as well as in N1 and N2 cancers in separate.
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Introduction
Local recurrence was a major problem in rectal cancer be-
fore the introduction of the total mesorectal excision
(TME). Swedish rectal cancer trial showed that neoadju-
vant short-course radiotherapy (RT) reduced the local re-
currence risk and improved survival in patients operated
on before the adoption of the TME technique [1, 2].
Dutch trial found that short-course radiotherapy reduced
the risk of local recurrence when combined with TME
surgery, however, without any beneficial effect on survival
[3–5]. It was reported that there was 10.6% local recur-
rence risk in stage III disease after short-course RT com-
bined with TME and 20.6% local recurrence risk in those
treated with TME alone [4]. On the other hand, a local re-
currence rate of 4% with meticulous TME surgery alone
has been reported and no difference in local recurrence
rate between stage II and III disease was noted in that
series [6–8]. Efforts have also been made to recognize the
so-called “good” prognosis T3 cancers and separate them
from “poor” prognosis T3 cancers [8, 9]. However, we do
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not know if the patients with ugly T3 cancer benefit from
short-course RT.
Short-course RT can cause harm. It increases the leak-
age risk of colorectal anastomosis, and it can cause bowel,
urinary, and sexual dysfunction [10–14]. It is also sus-
pected to have a higher incidence of secondary malignan-
cies after radiotherapy [15].
At the present, there are remarkable differences in pre-
operative treatment strategies of rectal cancer in European
countries [16]; Sweden and the Netherlands use neoadju-
vant short-course RT most often, but in Norway and
Denmark, short-course RT is little used as a treatment op-
tion. Despite this, there are no remarkable differences be-
tween the oncological treatment results of these countries.
The treatment strategy of rectal cancer in our unit is
very similar to that of Sweden; most patients with T3 tu-
mors and a suspicion of positive lymph node involve-
ment receive short-course neoadjuvant RT. However,
diagnosis of positive lymph node involvement in rectal
MRI is difficult, as shown by high-quality units [8], and
some patients are not suitable for RT for other reasons;
therefore, there are still substantial numbers of patients
with pT3N1-2 rectal cancer whom have not undergone
short-course RT preoperatively.
The first aim of this study was to evaluate the effect of
short-course RT on local recurrence risk in patients that
have pT3N1-2 rectal cancer in pathological specimen.
The second aim was to compare risk factors between pa-
tients that had short-course neoadjuvant RT before TME
surgery and those that had TME surgery alone.
Materials and methods
Patient characteristics
A total of 151 patients, having had pT3N1-2M0 rectal
cancer and TME, operated on in Helsinki University Hos-
pital over the beginning of 2005–June 2014 period were
included in retrospective analysis. In all, 952 patients were
operated on for rectal cancer in our unit during this same
time period. Short-course neoadjuvant radiotherapy (5 × 5
Gy) was given to 94 patients, and they were operated on
within 5 days after RT (the RT plus surgery group). Fifty-
seven patients were operated on without neoadjuvant
therapy (the surgery only group). Patients underwent
whole-body computer tomography (CT) and magnetic
resonance imaging (MRI) of the rectum for the preopera-
tive staging of disease. Histology of the tumor was subse-
quently verified by preoperative endoscopy biopsies. The
necessity of neoadjuvant RT was determined in a multidis-
ciplinary team meeting that comprised colorectal surgeon,
an oncologist, a radiologist, and a pathologist. The pa-
tients, who were evaluated to have rT2-T3N0 tumor on
the basis of preoperative MRI, did not receive RT. Some
patients with rT3N1-2 tumor were not able to be treated
with neoadjuvant RT because of previous pelvic RT for
other reasons. The CRM was not threatened based on
MRI in the study group. The data were collected from pa-
tient records after at least 2 years of follow-up.
The median follow-up time for the whole patient
group was 4.3 (range 0.01–11.3) years. The follow-up
time was defined as time in years from the day of sur-
gery until the last contact day with the health care sys-
tem or death. The cause of death was verified from
official death certificates. One patient died during the
30-day postoperative period due to pulmonary embol-
ism. This patient was excluded only from the risk factor
analysis for local recurrence. No patient was lost to
follow-up. The local ethics committee approved the
study protocol. Patient and disease characteristics are
shown in Tables 1 and 2.
The rectal cancer was operated on using the TME tech-
nique; the operation in the upper rectum was by partial
mesorectal excision (PME). A colonic J-pouch was routinely
constructed in operations for middle and low rectal tumors.
Table 1 Patient characteristics
Characteristics Surgery only,
N = 57 (%)
Radiotherapy plus
surgery, N = 94 (%)
p
Follow-up time 0.62
Median (years) 4.0 4.4
Range (years) 0.2–11.2 0.01–11.3
Age 0.01
Median (years) 71 66
Range (years) 32–88 37–86
Gender 0.87
Male 28 (49) 44 (47)
Female 29 (51) 50 (53)
BMI 1.0
≤ 25 kg/m2 23 (40) 44 (47)
> 25 kg/m2 19 (33) 38 (40)
Missinga 15 (27) 12 (13)
Tumor distance from anal verge 0.17
≤ 6 cm 17 (30) 39 (42)
> 6 cm 40 (70) 55 (58)
Type of surgery 0.10
Anterior resection (AR) 40 (70) 78 (83)
Abdominoperineal excision
(APE)
11 (19) 13 (14)
Hartmann’s procedure 6 (11) 3 (3)
Macroscopically curative
surgery
56 (98) 93 (99) 1.0
Postoperative chemotherapy 35 (61) 82 (87) <
0.001
Death 24 (42) 27 (29) 0.11
Cancer-related death 17 (30) 20 (21) 0.25
aData not available, not included in p level count
Räsänen et al. World Journal of Surgical Oncology          (2019) 17:139 Page 2 of 7
The covering stoma was performed in 121 patients. The
macroscopic result was considered compromised if either
spontaneous or iatrogenic tumor perforation occurred or if
the surgeon thought that the resection margin might be in-
volved. Tumor location 6 cm or under from anal verge was
chosen as one variable for local recurrence risk factor ana-
lysis, because these low cancers are known to carry an in-
creased risk for local recurrence [17].
Postoperatively, 31 patients received adjuvant therapy
for 6 months and 4 patients chemoradiation. The mainly
used adjuvants were single capecitabine and oxaliplatin
with capecitabine, alone or with bevacizumab.
The rectal cancer patients were followed up according to
a predetermined schedule. The healing of colorectal anas-
tomosis was evaluated after 6 weeks by fiberosigmoido-
scopy. After this, the follow-up visits were held biannually
for the first 2 years and annually thereafter for up to 5
years. Fiberosigmoidoscopy or colonoscopy was performed
at every visit up to 2 years, and colonoscopy was performed
at 5 years. The levels of hemoglobin and carcinoembryonic
antigen (CEA) were measured at every follow-up visit. A
CT or MRI was taken only when disease recurrence was
suspected based on clinical examination or symptoms, be-
cause the radiological examinations were not included in
the routine follow-up protocol during the study period.
Statistical analysis
The cumulative survival and the cumulative local recur-
rence risk were calculated by the Kaplan-Meier method.
The potential risk factors for local recurrence were ana-
lyzed by the univariate Cox regression test. In multivari-
ate analysis, tumor distance, mucinous histology, and
lateral margin were included into the model, based on
our previous article [17]. In addition, preoperative short-
course RT was included. Differences between the two
patient groups were analyzed by using Fisher’s exact test
(dichotomous), the Mann-Whitney- test (continuous),
and linear-by-linear test (ordinal by ordinal). Exact 95%
confidence intervals (CIs) were calculated for difference
in proportions. p values below 0.05 were considered sig-
nificant, and all statistical tests were two-sided. Statis-
tical analyses were run on SPSS version 23.0 (SPSS,
IBM, Armonk, NY, USA) and StatExact version 4.0
(Cytel Software corporation, Cambridge, MA, USA).
Results
Median follow-up and survival rates
The median follow-up time was 4.3 (range 0.01–11.3)
years for the whole patient population, 4.0 (0.2–11.2)
years for the surgery only group and 4.4 (0.01–11.3)
years for the RT plus surgery group. Fifty-one patients
(33.8%) died during the follow-up period, 37 (24.5%) for
cancer-related reasons. The 30-day postoperative mor-
tality was 0.7%.
The cumulative overall survival at 1-, 3-, and 5-year in
the whole 151 patient population was 92.7%, 81.1%, and
68.9%. In separate groups, the overall 1-, 3-, and 5-year
survivals were 94.7%, 78.6%, and 59.2% for the surgery
only group and 91.5%, 82.6%, and 75.2% for the RT plus
surgery group (p = 0.13). The cancer-related overall 1-, 3-,
and 5-year survival in the whole 151 patient population
was 94.6%, 86.9%, and 73.9%. In separate groups, the
cancer-related 1-, 3-, and 5-year survival was 98.2%,
87.1%, and 65.6% for the surgery only group and 92.5%,
86.7%, and 79.0% for the RT plus surgery group (p = 0.24).
Local recurrence
Local recurrence afflicted 17 (11.3%) of 150 patients, 8 of
57 (14.0%) patients in the surgery only group and 9 of 93
patients (9.7%) in the RT plus surgery group (p = 0.44).
The difference of proportions between the groups is −
4.3% (95% CI − 21.9 to + 8.6%). The median time for local
recurrence in 17 patients was 2.8 (0.3–5.3) years. The me-
dian time to local recurrence was 2.0 (range 0.3–3.6) years
for the surgery only group and 2.8 (0.7–5.3) years for the
RT plus surgery group (p = 0.24). There was no significant
difference in local recurrence between the surgery only
and in RT plus surgery groups (p = 0.36) in the Kaplan-
Meier analysis. The 2-, 3-, and 6-year cumulative risk for
local recurrence was 7.3% (2 years), 12.0% (3 years), and
17.5% (6 years) in the surgery only group and 4.6% (2
years), 6.0 % (3 years), and 14.0% (6 years) for the RT plus
surgery group (Fig. 1).
Table 2 Disease characteristics
Characteristics Surgery only,
N = 57 (%)
Radiotherapy plus
surgery, N = 94 (%)
p
Histology 0.76
Adenocarcinoma 48 (84) 82 (87)
Mucinous carcinoma 9 (16) 11 (12)
Neuroendocrine carcinoma 0 1 (1)
Grade 0.87
1 4 (7) 5 (5)
2 41 (72) 74 (79)
3 10 (18) 13 (14)
4 0 (0) 2 (2)
Missinga 2 (3) 0
pN 0.62
1 33 (58) 50 (53)
2 24 (42) 44 (47)
Lateral margin R1 (< 1 mm) 6 (11) 6 (6) 0.37
Tumor perforation 5 (9) 2 (2) 0.10
Invasion 0.04
Vascular/neural/lymphatic 15 (26) 41 (44)
aData not available, not included in the significance test
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Risk factor for local recurrence
Neoadjuvant short-course RT did not affect the risk of
local recurrence after surgery of pT3N1-2M0 rectal can-
cer as analyzed in the univariate Cox regression model.
The risk factors for local recurrence for the entire 150
patient population were the following: involved lateral
margin (< 1 mm) in specimen (p < 0.001), tumor perfor-
ation (p < 0.001), tumor location under 6 cm from anal
verge (p = 0.01), and mucinous histology (p = 0.006).
Patient-related factors (gender, age, BMI), type of oper-
ation, 30-day anastomotic complications, invasion of
vessels, nerves or lymphatics, or preoperative short-
course radiotherapy did not affect the risk of local recur-
rence (Table 3). The risk factors for local recurrence an-
alyzed in the multivariate analysis were the following:
involved lateral margin (p < 0.001) and tumor location
under 6 cm from anal verge (p = 0.03), but not neoadju-
vant RT or mucinous histology. Also, subgroup analysis
between males and females having tumor under 6 cm
from the anal verge was calculated by Fisher’s exact test,
and no significant difference between genders was no-
ticed (p = 1.00).
Discussion
We found that neoadjuvant short-course RT was not a
preventive factor for local recurrence in patients oper-
ated for pT3N1-2M0 rectal cancer in our dataset. Any-
how, all surgical procedures executed in the present
study used the TME-technique, which is fundamental
for the adequate dissection in a rectal cancer operation
[7], and has better local control compared to blunt dis-
section [18]. Our data comprised only of patients with
stage III diseases assessed by pathology report postoper-
atively. The total local recurrence rate for all the patients
was 11.3%, for the RT plus surgery group 9.6% and for
the surgery only group 14.0%. Thus, these findings are
in line with a previously published local recurrence rate
[19] and the difference between groups was not signifi-
cant. A Dutch trial found that the local recurrence rate
at 5 years was 9.3% for the RT plus surgery group and
19.4% for the surgery only group in stage III disease
[20]. A Norwegian study, reporting the results of T3 rec-
tal cancers treated with curative intention with TME
without neoadjuvant treatment, observed a 3-year local
recurrence rate to be about 18% for T3N1 tumors and
about 24% for T3N2 tumors [9]. Possibly, the quality of
TME in the early phase of that study, i.e., when TME
was novel, in some of the centers might not have been
at as high level as would be the case nowadays. More-
over, a series that included patients operated on before
and after the adoption of the TME technique found the
local recurrence risk for T3N1-2 patients to range be-
tween 34.5 and 42.9% [21].
The median time to local recurrence in our series
seemed to be shorter in the surgery only group than for
the RT plus surgery group (2.0 vs. 2.8 years). A similar
pattern was also reported in the Dutch TME trial [20].
However, more patients in the RT plus surgery group in
our study received adjuvant chemotherapy than in the
surgery only group (87% vs. 61%), which may also have
delayed the emergence of local recurrence. In our unit,
patients with evidence of positive lymph node involve-
ment in their specimen are evaluated by an oncologist
for possible suitable adjuvant treatment, but not
Fig. 1 Cumulative risk of local recurrence between the surgery only and radiotherapy plus surgery groups in Kaplan-Meier analysis
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everyone receives chemotherapy because of patient-
related factors, such as fragileness or prolonged recovery
or refusal of such treatment by some patients.
Several studies have tried to separate good prognosis T3
tumors from poor prognosis T3 disease, both before and
after TME era [8, 9, 21]. Those T3 tumors, predicted to
have less than 5mm spread from the muscularis propria
in MRI, have a minor risk for local recurrence after sur-
gery without RT, regardless of lymph node involvement
status [8, 21]. In the early days of this study period, the T3
tumors were not divided into four subclasses by an MRI
radiologist; thus, we do not know the distribution to rT3a-
d subclasses. However, there were more tumor perfora-
tions in the non-irradiated group, which suggests that tu-
mors in this group were locally more advanced.
In our study, 38% of pT3N1-2 patients did not receive
neoadjuvant RT, even though our treatment strategy has
been to irradiate T3 tumors when there is suspicion of
lymph node involvement upon MRI. There are several
reasons for this. First, the MRI diagnosis of lymph node
involvement is difficult. Only half of the “good” prognosis
patients with positive lymph node involvement in the
MERCURY study had been evaluated to have had positive
lymph node involvement in the preoperative MRI [8].
Second, some of our patients had received previous pelvic
irradiation for other reasons and the neoadjuvant RT for
rectal cancer was thereby contraindicated. Third, some
other patient-related factors, such as difficult dementia or
otherwise poor cooperation, may have been a reason not
to offer RT.
The main risk factors for local recurrence in this specific
group, pT3N1-2M0 rectal cancer in our analysis, were as
follows: involved CRM, tumor distance under 6 cm from
anal verge, and tumor perforation. All these risk factors
for local recurrence have already been acknowledged in
many studies [3, 9, 22] and also in the data of our earlier
published study [17]. A Dutch study reported the risk fac-
tors for local recurrence to be stage IV disease, T4 tumor,
positive CRM in T3 or T4 tumors, and also N2 disease
[20]. The preoperative RT did not prevent local recur-
rence in our study patients with stage III disease.
One reason for the critical evaluation of the usefulness
of preoperative RT in this setting is its possible toxicity.
Low anterior resection syndrome and poor functional out-
come occur more often in patients who receive RT com-
pared to patients whom have had surgery only [10, 13]. A
recovery to daily activity is also slower after having re-
ceived RT. Sexual dysfunction is a problem, as well [11,
12, 23]. Radiotherapy is found to be a risk factor for anas-
tomotic leakage, which in itself may prevent adjuvant
chemotherapy and also adversely affect bowel function
[14]. The wound healing after abdominoperineal excision
(APE) is slower after RT than without it [3, 24]. More sec-
ondary malignancies are reported to occur after RT (9.5%
compared surgery only 4.3%) in irradiated areas [15].
More than 50% of patients report long-term side effects
after having RT [23].
In the light of the data available including those of the
present study, the efficacy of neoadjuvant short-course
RT in T3N+ rectal cancer is uncertain and needs to be
studied more. Radiotherapy decreased the amount of
local recurrences before the TME era [1]. During the
learning phases of TME surgery soon after its adoption,
RT still had a beneficial effect on the local recurrence
rate of tumors with positive lymph node involvement, at
least in multicenter studies [3, 4]. It is also possible that
multicenter studies [3, 4] also included centers of lower
technical quality. However, other more current studies
Table 3 95% confidence intervals Cox regression univariate and multivariate analysis of risk factors expressed as hazard ratios for
local recurrence in 150 patients
Variable Cox regression univariate analysis Cox regression multivariate analysis
HR 95% Cl p HR 95% Cl p
Gender (male) 1.14 0.44–3.00 0.79
Age (≤ 65 years) 1.23 0.47–3.23 0.68
BMI (≤ 25 kg/m2) 0.56 0.19–1.64 0.29
Tumor ≤ 6 cm distance from anal verge 3.52 1.30–9.56 0.01 3.33 1.11–9.98 0.03
Preoperative short-course radiotherapy 0.65 0.25–1.67 0.37 0.58 0.22-1.55 0.28
APE compared to AR operation 1.19 0.34–4.16 0.78
Mucinous histology 3.99 1.47–10.80 0.006 0.60 0.60–5.92 0.28
Involved lateral margin 7.90 2.75–22.74 < 0.001 6.40 2.01–20.36 0.002
Tumor perforation 8.31 2.70–25.53 < 0.001
Invasion of vessels/nerves/lymphatics 2.43 0.93–6.33 0.07
Early anastomotic complication 2.44 0.70–8.49 0.16
Grade 1–2/3–4 1.57 0.45–5.53 0.48
HR hazard ratio, CI 95% confidence interval, BMI body mass index, AR anterior resection (included Hartmann’s procedure), APE abdominoperineal excision
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showed that even lower recurrence rates can be achieved
by using meticulous TME surgery alone and the results
were not poorer for lymph node positive disease, at least
in good prognosis T3 tumors [7, 8]. The adoption of neo-
adjuvant short-course RT in rectal cancer treatment has
taken place within the same time period as TME tech-
nique, and MRI-directed multidisciplinary teams in de-
signing the treatment for each patient have become a
standard, both of which have been shown to improve
oncological results [2, 18, 22, 25]. T3c-d tumors seem to
have poorer prognosis in terms of local recurrence, but it
is still not known whether that subgroup of tumors would
eventually benefit from preoperative short-course RT.
Our current data on pT3N1-2 tumor outcome suggests
that the routine use of neoadjuvant short-course RT in
T3N+ rectal cancer patients may not be justifiable for all
patients. However, patient number in our study was small
and patient groups may not be quite equivalent due to
retrospective nature of the study. Thus, the possible bene-
ficial effect of neoadjuvant RT may not manifest. Further,
due to limited number of patients in our study, different
T3 subgroups (T3a–c) as well as N1 and N2 patients
could not be separately studied. Thus, some subgroup
possibly having advantage of short-course radiotherapy
could not be recognized.
In conclusion, neoadjuvant short-course RT did not
beneficially affect the local recurrence rate of pT3N1-2M0
rectal cancer in our retrospective series. Since short-
course RT also has potential side effects, its role as routine
neoadjuvant treatment in T3N+ disease should be critic-
ally considered. However, further studies with larger pa-
tient numbers on pT3b-c rectal cancer and in N1 and N2
disease are needed to evaluate the value of neoadjuvant
therapy in these particular groups.
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